iBio Inc (IBIO) FinancialsIBIOFinancialiBio Inc

iBio Inc (IBIO) generates its revenue primarily from iBio CDMO, which accounts for 100.0% of total sales, equivalent to $61.00K. Understanding this concentration is critical for investors evaluating how IBIO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, iBio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -30138.00%, while the net margin is -33044.00%. These profitability ratios, combined with a Return on Equity (ROE) of -65.70%, provide a clear picture of how effectively IBIO converts its operational activities into shareholder value.

In the context of the broader market, IBIO competes directly with industry leaders such as UPXI and FTLF. With a market capitalization of $71.04M, it holds a significant position in the sector. When comparing efficiency, IBIO's gross margin of N/A stands against UPXI's 93.11% and FTLF's 36.01%. Such benchmarking helps identify whether iBio Inc is trading at a premium or discount relative to its financial performance.

iBio has shown a gross margin of 100% in recent quarters, which is impressive, but it has reported significant net losses, including -$7.73 million in Q3 2026. Total revenue has been inconsistent, with only $200,000 reported in Q2 2025 and Q4 2025.